medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (6)


Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma

Dido BV, Alves MA, Perdomo CG, Branco AF, Marroni CA, de Mello BAB, Ott FPR, Schmidt CCT, Atalibio HA, Kretzmann FNA

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 899-906
Archivo PDF: 112.21 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.

  2. Roberts LR. Sorafenib in liver cancer-Just the beginning. N Engl J Med 2008; 359: 420-2.

  3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.

  4. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.

  5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.

  6. Brose MS, Smyrk T, Weber B, Lynch HT. Genetic predisposition to cancer-cancer etiology. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E (eds.). Cancer Medicine. Ontario, Canada: BC Becker; 2000, p. 168-84.

  7. The Human Genome. Disponível em: http://genome. wellcome.ac.uk/ [Acesso em: 28 de Março de 2011].

  8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.

  9. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.

  10. Huang JS, Zhang XJ, Xu X, Guan M, Zhou YL, Lü L, Zou HJ. Influence of MDR1 gene C3435T on peripheral white blood cell counts in workers exposed to benzene. Chi J Ind Hyg Oceup Dis 2011; 2: 20-3.

  11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, et al. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 2000; 97: 3473-8.

  12. Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-37.

  13. Jamroziak K, Miynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haemato 2004; 72: 314-21.

  14. Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T=A gene polymorphism is associated with high risk of lung cancer. Cancer 2006; 107: 2850-7.

  15. Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV. The mechanism of action of multi-drug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001; 33: 481-91.

  16. Avendano C, Menendez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002; 9: 159-93.

  17. Fromm MF. Genetically determined differences in P-glycoprotein function: Implications for disease risk. Toxicology 2002; 182: 299-303.

  18. Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB. P-glycoprotein expression is a marker for chemo therapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000; 20: 1061-7.

  19. Alves MTS, Miiji LNO, Marinho LC, Toledo SRC, Patrício FRS, Garcia-Filho RJ, Petrilli AS, et al. Osteossarcomas humanos de alto grau: imunoexpressão de p53, erb-2 e P-glicoproteína, e correlação com o parâmetro anaplasia. J Bras Patol Med Lab 2008; 44: 107-14.

  20. Sjöholm MI, Hoffmann G, Lindgren S, Dillner J, Carlson J. Comparison of archival plasma and formalin-fixed paraffin- embedded tissue for genotyping in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 251-5.

  21. Silva M, Mattos AA, Fontes PR, Waechter FL, Pereira-Lima L. Evaluation of hepatic resection for hepatocellular carcinoma on cirrhotic livers. Arq Gastroenterol 2008; 45: 99-105.

  22. Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, et al. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol 2010; 1: 63-9.

  23. Huang CC, Wu MC, Xu GW, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84: 262-64.

  24. Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007; 38: 539-44.

  25. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010: 12: 34-40.

  26. Siegsmund M, Brinkmann U, Scháffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-54.

  27. Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Firouzi F, Aghazadeh R, Daryani NE, et al. The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int J Colorectal Dis 2007; 22: 999-1003.

  28. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 2005; 59: 365-70.

  29. Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 2007; 96: 62-8.

  30. Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, Liang H, et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010; 96: 90-6.

  31. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.




2020     |     www.medigraphic.com